WEST BRIDGEWATER, Mass.,
Jan. 19, 2022 /PRNewswire/
-- Theromics Inc., a medical device company pioneering novel
technologies for interventional radiology and drug delivery, has
closed a $2M seed equity financing to
advance the development of HeatSYNC™, a thermal accelerant gel for
optimizing and augmenting soft tissue thermal ablations.
Participants in the round include Maroon Venture Partners,
Beacon Angels Boston, STARmed Co. Ltd, and individual investors.
Theromics will use the financing to advance HeatSYNC through the
FDA-required testing for regulatory clearance. The studies are
currently underway or planned to occur at distinguished research
institutions, including Dartmouth
College, Brown University,
Purdue University, and Kansas State University.
"Theromics has developed a simple, unique approach to making
soft tissue ablation more effective. The closing of our initial
funding validates clinicians' opinion that additional tools are
needed to elevate thermal ablation to front-line therapy," stated
Theromics CEO Ronald Murphy.
The Company has also announced that John L Brooks III will be
joining the Theromics Board of Directors. John L. Brooks III is the Managing Director of
Healthcare Capital LLC, which advises early-stage life sciences
companies. He is the former President and Chief Executive Officer
of the Joslin Diabetes Center and has co-founded seven life
sciences companies, including Insulet (PODD), a disruptive insulin
delivery company. In addition, he was a co-founder of Prism Venture
Partners, a $1.25B venture capital
firm, and currently sits on the investment team at Maroon Venture
Partners.
Mr. Brooks noted, "Theromics is developing an exciting new
platform with multiple applications in the growing fields of soft
tissue ablation and locally directed drug delivery. We are excited
to be partnering with the team and supporting UMass-trained entrepreneurs like Dr. Damian Dupuy, one of the Company's
founders."
About HeatSYNC™
Theromics has developed a simple,
cost-effective tool to address the unmet medical need to create
more effective ablation zones during Image-Guided Thermal Ablation
of soft tissue. HeatSYNC™ Gel is a novel biopolymer
thermal-accelerant that amplifies the movement of heat energy in
soft tissue and bone. The gel is made from a naturally occurring
protein and delivered via a syringe, laparoscope, or bronchoscope.
In addition, all standard microwave, RF, and Irreversible
electroporation (IRE) devices can use HeatSYNC, and its
chemical properties augment the energy generated from the ablation
system. This augmentation is controllable, customizable, and
creates larger ablation volumes in a shorter treatment time.
HeatSYNC also blocks complete energy penetration, mitigating the
effects of heat sinks and protecting critical tissue. As a result,
HeatSYNC gel has multiple liver, lung, orthopedic pain, and uterine
fibroid treatment applications. After successful animal trials, the
Company is now positioned for formal GLP gel testing, leading to an
FDA submission.
About Theromics Inc.
Theromics is developing a
next-generation thermal accelerant technology for soft tissue
ablation procedures and combination therapy. The Company's
proprietary HeatSYNC™ gel is based on a protein naturally
found in the body and may increase cost-efficiencies and improve
outcomes through more focused and patient-centric delivery.
The Company will first focus on tumor ablations and then expand
into additional applications, including pain and abnormal uterine
bleeding. Longer-term, Theromics plans to apply its thermal
technology for use as an oncolytic intratumoral drug/immunotherapy
delivery platform with the potential to enhance efficacy and
improve safety profiles of currently approved medicines. For more
information, visit www.theromicsinc.com.
Contact Information:
Theromics Inc.
Ronald Murphy CEO
(508) 942-8477
View original
content:https://www.prnewswire.com/news-releases/theromics-inc-announces-closing-of-oversubscribed-2m-seed-series-and-names-john-brooks-iii-to-board-of-directors-301464132.html
SOURCE Theromics Inc.